CerusCERS
About: Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.
Employees: 280
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
364% more call options, than puts
Call options by funds: $357K | Put options by funds: $77K
7% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 41
1.29% less ownership
Funds ownership: 81.18% [Q1] → 79.89% (-1.29%) [Q2]
3% less funds holding
Funds holding: 144 [Q1] → 140 (-4) [Q2]
7% less capital invested
Capital invested by funds: $278M [Q1] → $260M (-$18.2M) [Q2]
17% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 24
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
Stifel Mathew Blackman 43% 1-year accuracy 6 / 14 met price target | 84%upside $3 | Buy Maintained | 17 Oct 2024 |